Related Experiment Videos
[Evidence based chemotherapy for lung cancer]
1Dept. of Internal Medicine, National Cancer Center Hospital.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|February 8, 2000
Summary
Clinical trials are crucial for evidence-based cancer treatment, especially for small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). New drug combinations show promise, but further research is needed to establish optimal therapies and improve patient survival.
Area of Science:
- Oncology
- Clinical Trials
- Evidence-Based Medicine
Context:
- Experience-based medicine lacks a strong foundation; therapy should rely on the highest available evidence.
- Uncertainty in clinical cancer practice necessitates generating new evidence through clinical trials.
- Organizing multi-institutional clinical trials in Japan is an urgent priority.
Purpose:
- To review current evidence-based treatment standards for small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC).
- To identify areas of uncertainty and the need for new clinical trials.
- To evaluate the efficacy of novel chemotherapeutic agents and combinations.
Summary:
- Limited disease SCLC: Concurrent chemoradiotherapy with cisplatin and etoposide is standard.
- Extensive disease SCLC: PE or CAV/PE chemotherapy is standard; new drugs show promise.
- NSCLC (Stage III/IV): Cisplatin-based chemotherapy with radiotherapy improves survival; optimal sequencing and new drug combinations are under investigation. Second-line docetaxel improves survival in platinum-pretreated patients.
Impact:
- Highlights the need for robust clinical trials to guide cancer treatment decisions.
- Identifies promising new drug combinations for SCLC and NSCLC that warrant further investigation.
- Emphasizes the importance of establishing evidence-based standards for optimal patient outcomes.